[Antibody tests for COVID-19: What the results tell us].

Antikörpertests bei COVID-19 - Was uns die Ergebnisse sagen.

Journal

Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen
ISSN: 2212-0289
Titre abrégé: Z Evid Fortbild Qual Gesundhwes
Pays: Netherlands
ID NLM: 101477604

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 23 04 2020
accepted: 06 05 2020
pubmed: 19 5 2020
medline: 5 9 2020
entrez: 19 5 2020
Statut: ppublish

Résumé

In the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, the detection of virus-specific antibodies (AB) will play an increasing role. The presence or absence of such antibodies can potentially lead to considerations regarding immunity and infection. How reliable are inferences from positive or negative test results regarding the actual presence of SARS-CoV-2 specific antibodies? Calculation of the probability that, depending on the pretest probability (prevalence of SARS-CoV-2 infection) and test properties, antibodies are present or absent in the case of positive or negative test results. Sensitivity and specificity of different SARS-CoV-2 AB test systems vary between 53 % and 94 % and between 91 % and 99.5 %, respectively. When using a test with high test quality, the positive predictive value (PPV) is 42 % and 7 9%, respectively, with a pre-test probability of 1 % to 5 %, as can currently be assumed for the general population in Austria or Germany. For persons with an increased pre-test probability of 20 %, e. g. persons from high-risk professions, the PPW is 95 %, with a pre-test probability of 80 % the PPW is almost 100 %. The negative predictive value (NPV) is at least 99.7 % for persons with a low pre-test probability of up to 5 % and 79.1 % for persons with a pre-test probability of 80 %. When using test systems with lower sensitivity and specificity, the reliability of the results decreases considerably. The PPV is 5.9 % with a pre-test probability of 1 %. A sufficiently high sensitivity and specificity are prerequisites for the application of antibody test systems. Positive test results are often false if the pre-test probability is low. Depending on the assumed prevalence of a SARS-CoV-2 infection, there are substantial differences in the significance of a concrete test result for the respective affected persons.

Identifiants

pubmed: 32419875
doi: 10.1016/j.zefq.2020.05.005
pii: S1865-9217(20)30049-0
pmc: PMC7225716
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article

Langues

ger

Sous-ensembles de citation

IM

Pagination

54-59

Informations de copyright

.

Références

Nat Microbiol. 2019 May;4(5):734-747
pubmed: 30886356
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209385
JAMA. 2020 May 19;323(19):1881-1883
pubmed: 32301958
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
J Vet Sci. 2010 Jun;11(2):165-7
pubmed: 20458159
Immunol Lett. 2009 Aug 15;125(2):79-85
pubmed: 19539648
Diagnostics (Basel). 2020 May 19;10(5):
pubmed: 32438677

Auteurs

Karl Horvath (K)

Institut für Allgemeinmedizin und evidenzbasierte Versorgungsforschung, Medizinische Universität Graz, Österreich; Universitätsklinik für Innere Medizin, Klinische Abteilung für Endokrinologie und Diabetologie, Medizinische Universität Graz, Österreich. Electronic address: karl.horvath@medunigraz.at.

Thomas Semlitsch (T)

Institut für Allgemeinmedizin und evidenzbasierte Versorgungsforschung, Medizinische Universität Graz, Österreich.

Klaus Jeitler (K)

Institut für Allgemeinmedizin und evidenzbasierte Versorgungsforschung, Medizinische Universität Graz, Österreich; Institut für Medizinische Informatik, Statistik und Dokumentation, Medizinische Universität Graz, Österreich.

Robert Krause (R)

Universitätsklinik für Innere Medizin, Sektion für Infektiologie und Tropenmedizin, Medizinische Universität Graz, Österreich.

Andrea Siebenhofer (A)

Institut für Allgemeinmedizin und evidenzbasierte Versorgungsforschung, Medizinische Universität Graz, Österreich; Institut für Allgemeinmedizin, Goethe-Universität Frankfurt am Main, Deutschland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH